Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability.
Saved in:
| Title: | Response to the letter of Peng Bai and Jun Zhang on Cost-effectiveness of Adjuvant Alectinib in ALK-positive NSCLC-Considerations for Broader Applicability. |
|---|---|
| Authors: | Supiot R; Putnam Associates, HTA & Market Access, Paris, France. Electronic address: romain.supiot@putassoc.com., du Manoir de Juaye L; Roche S.A.S, Health Economics Unit, Boulogne-Billancourt, France., Chouaid C; Centre Hospitalier Intercommunal de Créteil (CHIC), Service de Pneumologie, Créteil, France; Université Paris-Est Créteil (UPEC), Créteil, France. Electronic address: Christos.chouaid@chicreteil.fr. |
| Source: | Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 Mar; Vol. 213, pp. 108944. Date of Electronic Publication: 2026 Jan 26. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
